Oct 17, 2023 Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia Learn More
Oct 2, 2023 Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants Learn More
Sep 18, 2023 Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia Learn More
Sep 11, 2023 Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing Learn More